熱門資訊> 正文
Spyre在200万美元的内部出售后倒闭
2026-06-24 22:39
- Anti-inflammatory drug developer Spyre Therapeutics (SYRE) lost ~10% on Wednesday, potentially on track to record its biggest one-day decline in more than a year after its director, Michael Henderson, sold $2M worth of company stock.
- The biotech executive sold 20K Spyre (SYE) shares for $100 apiece as part of a pre-arranged stock trading plan that complies with the SEC's insider trading rules, according to a regulatory filing on Tuesday.
- His stake in Spyre (SYRE) fell 23% to roughly 68.6K shares after Monday’s transaction, the SEC filing indicated.
- Henderson also serves as the CEO of Apogee Therapeutics (APGE), which agreed to be acquired by AbbVie (ABBV) in an all-cash deal worth $10.9B on Monday. Before that, he was the chief business officer at cardiology drug developer BridgeBio Pharma (BBIO).
More on Spyre Therapeutics
- Spyre Therapeutics, Inc. (SYRE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
- Spyre Therapeutics: Strong SPY001 Data Set Up A Catalyst-Rich 2026
- Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis - Slideshow
- Spyre Therapeutics GAAP EPS of -$0.74 misses by $0.05
- Spyre Therapeutics prices upsized $403M stock deal; gross proceeds exceed initial $300M goal
推薦文章
港股周報 | 市場風格切換！存儲、光通信股暴跌，科指反彈近6%；花旗稱科網股估值極具吸引力；創新葯、機器人概念飆漲
一周IPO | 史上最大ADR來襲！SK海力士或下周五登陸美股；16只新股即將上市！「今年最貴新股」鼎泰高科火熱招股中
年中盤點 | 存儲概念「強者恆強」！閃迪年內狂飆858%霸榜美股升幅Top10，康寧勢將成為下半年最大黑馬？
一周財經日曆 | 美聯儲會議紀要重磅來襲；SK海力士擬7月10日登陸美股；智譜、MiniMax限售股將解禁
華盛早報 | 美股冰火兩重天！道指狂飆近600點，存儲卻遭恐慌性拋售；「大空頭」Burry唱空美股半導體面臨30%回調
7月3日外盤頭條：特朗普2025年交易逾2.1萬筆 霍爾木茲海峽不復往日 微軟計劃8月推出Copilot全端整合產品
美股前瞻 | 美國6月非農大幅低於預期！納指期貨轉漲至0.5%；馬斯克稱特斯拉機器人產線或已就緒；英偉達祭出AI工廠分成模式
華盛早報 | AI硬件股集體「熄火」！閃迪、美光暴跌10%，韓股開盤即熔斷；蘋果醖釀採購中國存儲芯片
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
